| |
Featured Product
In our efforts to keep you informed of all developments within the R&D community, here is our most recently featured product:
Treprostinil Sodium CAS# 163521-12-8
 LGM Pharma works closely with educational institutions that are actively developing and improving existing treatment options for patients suffering from Pulmonary Arterial Hypertension.
This product is available with a US-DMF, and our company's promise of timely delivery and adherence to international regulatory standards. Institutions can focus entirely on their progects, knowing that their supplier of research molecules (e.g. treprostinil sodium CAS# 289480-64-4) are reliable and reputable in the world of the pharmaceutical supply chain.
Read More >
LGM Pharma Works with Overseas Providers to Assure Quality Control of Pharmaceuticals
 As is the case in almost every industry, pharmaceutical manufacturing is becoming an increasingly global business. Between 2001 and 2008, the number of drugs produced outside the U.S. doubled. While this certainly reduces production costs for manufacturers and potentially reduces the costs that consumers pay for pharmaceuticals, the safety of the drugs may be sacrificed in the process. When the manufacturers outsource their production, the level of actual control for both the manufacturer and the Food and Drug Administration (FDA) is effectively reduced....
Read More >
|
|
|
|
Recent Videos
LGM Pharma - Active Pharmaceutical Ingredient Supplier
Posted on: 11/16/11
Recent Blog Posts
Ancrod present favorable benefit-risk outcomes in ischemic stroke patients
Posted on: 11/4/11
 A randomized controlled study done by David G. Sherman et al. in community hospitals across the US and Canada found favorable outcomes in ischemic stroke patients being treated with Ancrod within 3 hours of the onset compared to those who were on placebo. Mortality rates were not significantly different between the two groups but the functional disability of those patients on placebo was higher than those treated with Ancrod. These results proved that Ancrod presents improved clinical outcomes for ischemic stroke patients... More >
|
|
|
